profit from every $100 of sales.
$0$100
Neonc Technologies Holdings
$4.52+3.43% today
-60.4% in 1 year
1-year low $2.531-year high $11.83
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Neonc Technologies Holdings sold, what it kept, and what it did with the cash.
Sales went from $20,000 in 2022 to $39,990 in 2025, with -$62.1 million of profit last year.
SalesProfit
Neonc Technologies Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Neonc Technologies Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Neonc Technologies Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -3 | -8 | -7 | -58 | |
| -3 | -12 | -9 | -60 | |
| -3 | -15 | -12 | -62 | |
| -0.16 | -0.80 | -0.63 | -3.20 | |
| – | – | – | – | |
| -14,188.0% | -11,492.2% | -8,605.4% | -145,459.4% | |
| -15,233.8% | -21,176.0% | -14,335.5% | -155,404.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 1 | 3 | 3 |
| Cash | 1 | 0 | 0 | 0 |
| Total debt | 0 | 7 | 0 | 6 |
| Total liabilities | 2 | 15 | 9 | 20 |
| -2 | -14 | -6 | -18 | |
| 19 | 19 | 19 | 19 | |
| – | – | – | – | |
| 193.4% | 106.7% | 216.1% | 355.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -2 | -4 | -20 | |
| – | – | – | 1 | |
| -1 | -2 | -4 | -21 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 0 | 0 | 36 |
Valuation
- –
- –
- –
- -9.4×
- 3,260.9×
- –
- –
- -16.0%
- -47.7%
- 0.0%
Profitability
- 0.0%
- -145,459.4%
- -155,404.4%
- 0.0%
- 259.2%
- 555.2%
- 284.3%
- -1,160.3%
- 257.7%
- –
Growth
- +26.0%
- –
- –
- –
- –
Financial health
- –
- -0.03
- 10.4%
- -10.4×
- 0.08
- 0.08
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 21%of 890
Bottom 6%of 987
What analysts expect
- Average price target
- $15.00
- Range
- $15.00 – $15.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.38 | -0.22 | −73.5% |
| Mar 31, 2026 | -0.40 | -0.37 | −7.3% |
| Nov 14, 2025 | -0.45 | -0.37 | −21.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
11No pass
Benjamin Graham
4No pass
Philip Fisher
40No pass
Peter Lynch
–Not enough data
Joel Greenblatt
4No pass
Charlie Munger
35No pass
Terry Smith
33No pass
Questions about Neonc Technologies Holdings
Is Neonc Technologies Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Neonc Technologies Holdings AI analysis
What does Neonc Technologies Holdings do?
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is in Biotechnology.
Does Neonc Technologies Holdings pay a dividend?
No. Neonc Technologies Holdings does not pay a dividend at the moment.
Is Neonc Technologies Holdings stock halal?
Yes. Neonc Technologies Holdings passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Neonc Technologies Holdings stock done over the past year?
Down 60.4% over the past twelve months, to $4.52. It traded between $2.53 and $11.83 and is 61.8% below its high.
Who are Neonc Technologies Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Neonc Technologies Holdings's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.